Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma. [Phase 2]

View source ↗

Summary

A Phase 2 randomized study evaluates Autogene Cevumeran (RO7198457) plus pembrolizumab versus pembrolizumab alone in previously untreated advanced melanoma, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Autogene Cevumeran (autogene cevumeran)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Advanced Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2026-01-30